Merit Medical Systems, Inc.

Merit Medical Systems, Inc. (MMSI) Market Cap

Merit Medical Systems, Inc. has a market capitalization of $4.22B.

Financials based on reported quarter end 2025-12-31

Price: $70.93

0.83 (1.18%)

Market Cap: 4.22B

NASDAQ · time unavailable

CEO: Martha Goldberg Aronson

Sector: Healthcare

Industry: Medical - Instruments & Supplies

IPO Date: 1990-05-14

Website: https://www.merit.com

Merit Medical Systems, Inc. (MMSI) - Company Information

Market Cap: 4.22B · Sector: Healthcare

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.

Analyst Sentiment

85%
Strong Buy

Based on 11 ratings

Analyst 1Y Forecast: $102.92

Average target (based on 3 sources)

Consensus Price Target

Low

$78

Median

$103

High

$108

Average

$99

Potential Upside: 39.6%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 MERIT MEDICAL SYSTEMS INC (MMSI) — Investment Overview

🧩 Business Model Overview

Merit Medical Systems Inc. (MMSI) is a globally recognized manufacturer and marketer of medical devices used in interventional, diagnostic, and therapeutic procedures across a variety of medical specialties. The company's core focus areas include cardiology, radiology, oncology, critical care, and endoscopy, providing healthcare professionals with an extensive, innovative product portfolio that aims to enhance patient outcomes and workflow efficiency. The company maintains a vertically integrated manufacturing structure, enabling tight cost controls and quality assurance over a broad spectrum of proprietary and differentiated devices. Through direct sales channels in major markets and strategic partnerships or distributor networks in select geographies, MMSI continues to expand its international presence. The company's approach is characterized by physician engagement, ongoing product innovation, and targeted acquisitions, fostering a pipeline of solutions tailored to evolving clinical needs.

💰 Revenue Streams & Monetisation Model

Merit Medical's revenues predominantly derive from the sale of disposable medical devices and procedural solutions. The product portfolio spans over several primary categories: cardiovascular, peripheral intervention, oncology, endoscopy, and custom procedural kits. These products are generally single-use, driving recurring demand and reducing reliance on replacement cycles seen in capital equipment models. The company monetizes through direct sales to hospitals, clinics, and outpatient centers, as well as through group purchasing organizations (GPOs) and third-party distributors. The majority of its sales are generated from developed markets, but MMSI has strategically invested in emerging markets, seeking to diversify its payer and geographic mix. Merit supplements product revenue with select services, particularly in customized kit configurations and procedure support.

🧠 Competitive Advantages & Market Positioning

Merit benefits from several enduring competitive advantages: - **Product Breadth and Depth**: Its comprehensive range of devices enables bundled offerings, fostering stickier customer relationships while streamlining purchasing for healthcare providers. - **Intellectual Property Portfolio**: MMSI holds a significant number of patents and exclusive licenses, providing defensible market positions and barriers to entry in a number of device categories. - **Physician Engagement and Customization**: The company collaborates closely with clinicians to identify unmet needs, resulting in tailored device innovations and higher clinical adoption rates. - **Quality and Regulatory Track Record**: Merit’s established track record in navigating complex regulatory pathways in the United States and abroad enhances both its credibility and speed to market for new devices. - **Agile Manufacturing and Supply Chain**: Vertical integration affords margin advantages and responsiveness to fluctuating healthcare demand trends. Within its space, MMSI has differentiated itself against larger diversified medtech conglomerates with greater specialization, nimbleness, and a focus on procedural efficiency.

🚀 Multi-Year Growth Drivers

Several secular and company-specific trends position Merit Medical for sustainable multi-year growth: - **Aging Demographics and Chronic Disease Prevalence**: Rising incidence of cardiovascular disease, cancer, and other chronic conditions underpins robust baseline procedure growth. - **Shift to Minimally Invasive Therapies**: Provider and patient preference for less invasive, lower-cost interventions continues to drive adoption of Merit’s portfolio across interventional cardiology, radiology, and oncology. - **Portfolio Expansion and Innovation**: Ongoing R&D investment and clinical partnerships funnel a steady stream of new product launches and expanded indications within existing devices. - **Geographic Diversification**: Strategic expansion in underpenetrated regions (particularly Asia-Pacific and Latin America) offers additional runway for international growth. - **Value-Based Healthcare and Cost Containment**: Merit's solutions often focus on efficiency, workflow, and cost savings, aligning with broader healthcare system priorities. - **Select Acquisition Integration**: The company retains an opportunistic M&A strategy, bolstering its portfolio and global footprint with synergistic acquisitions.

⚠ Risk Factors to Monitor

Investors should remain aware of multiple risk factors inherent to Merit’s business and the broader medtech space: - **Regulatory and Compliance Risks**: The company faces ongoing risks related to product recalls, changing regulatory standards, and compliance with international requirements. - **Pricing Pressure**: Consolidation among hospitals and GPOs may heighten pricing competition. In addition, reimbursement changes or pressures can pose challenges to margins. - **Product Liability and Litigation**: As a manufacturer of invasive devices, Merit is exposed to potential product liability claims and associated litigation risk. - **Competitive Dynamics**: Larger, resource-rich rivals and startups alike compete intensely across the device market, putting innovation cycles and market share at risk. - **Operational Execution**: The complexity of managing global supply chains, especially in volatile environments, necessitates ongoing investment in logistics and inventory management. - **Foreign Exchange and Macro Risks**: With significant non-U.S. operations, MMSI is exposed to currency volatility and macroeconomic uncertainties in key growth markets.

📊 Valuation & Market View

Merit Medical is commonly valued in relation to its medical technology peers using revenue and EBITDA multiples, reflecting its recurring, largely consumable-driven business model and profitable growth profile. The investment community generally regards MMSI as a high-quality, mid-cap growth story with compelling cash flow generation and opportunities for both organic and acquisition-driven expansion. The company's margin profile reflects a combination of gross margin strength from proprietary products and operating leverage from scale, offset by recurring investments in R&D and sales infrastructure. Long-term valuation considerations factor in the durability of procedure growth, innovation pipeline, and management’s ability to deliver incremental margin expansion against a backdrop of healthcare cost pressure.

🔍 Investment Takeaway

Merit Medical Systems Inc. stands out as a differentiated, high-growth player within the global medical device industry. Its recurring revenue model, anchored by an expanding portfolio of consumable interventional devices, provides stability and visibility; while ongoing investment in innovation, physician collaboration, and international expansion support robust growth prospects. The company's competitive strengths, including a vertically integrated supply chain and deep clinical relationships, position it well to navigate sector headwinds such as regulatory scrutiny and pricing pressure. However, execution risks, regulatory vigilance, and competitive intensity remain persistent challenges. Overall, MMSI offers investors exposure to enduring healthcare trends of procedural growth and shift to minimally invasive care, balanced against sector-specific and execution-driven risks. Sustained success will depend on the company’s ability to further penetrate strategic markets, deliver differentiated solutions, and maintain its operational resilience.

⚠ AI-generated — informational only. Validate using filings before investing.

Merit delivered strong reported fundamentals in Q4—gross margin 54.5% (+103 bps YoY) and non-GAAP operating margin 21% (+138 bps YoY)—even with tariffs acting as an explicit headwind (112 bps incremental impact YoY). Management’s Q&A answers stress that incremental margin upside still relies on execution “more of the same”: mix/geo improvements, pricing discipline, cost reduction, and SKU rationalization rather than a new single catalyst. Analyst pressure in the gross margin question was whether the company has hidden opportunities or needs M&A/divestitures to sustain gains; management largely avoided a step-change narrative. The Rhapsody discussion also showed caution: the guide anchors to ~$7M starting point, but management admitted 2025 expectations “missed the mark” and framed 2026 as a planning number despite only ~4 months of outpatient nonhospital strategy execution, acknowledging competitive reaction. FCF guidance ($200M minimum) was described as conservative due to timing items the company can’t fully control, contrasting the confidence from 2025’s ~$216M result.

AI IconGrowth Catalysts

  • Cardiac Intervention (CI) sales up 21% in Q4; CI organic constant-currency growth 12% (excluding acquisitions)
  • Demand strength in EP/CRM (Prelude SNAP, Ventrax Delivery System) and angiography access (Prelude radial sheath; Prelude wave hydrophilic sheath introducer with SNAP Fix)
  • Peripheral Intervention (PI) sales up 13% and above expectations; radar localization + delivery systems up >25% and contributed 45% of PI growth
  • Custom Procedural Solutions (CPS) kit sales high teens growth (CPS total up 4%), offset by high single-digit declines in critical care products

Business Development

  • Acquired lead management products from Cook Medical; Biolife Delaware LLC; and C2 CryoBalloon device from PENTAX (inorganic revenue contribution in Q4: ~$10.8M)
  • Divested DualCap product line for $28M effective Feb 17, 2026; annualized 2025 revenue ~$20M; estimated 2026 revenue headwind ~140 bps to total constant-currency revenue growth

AI IconFinancial Highlights

  • Q4 revenue: $393.9M (+11% YoY GAAP; +10% YoY constant currency); constant-currency growth modestly above Q3 guidance high end
  • Q4 gross margin: 54.5% (+103 bps YoY; company’s highest quarterly gross margin); tariffs were a material headwind with 112 bps incremental impact YoY
  • Q4 non-GAAP operating margin: 21% (+138 bps YoY)
  • Q4 non-GAAP EPS growth: +12% YoY (exceeded high end of guidance by $0.03)
  • Q4 free cash flow (FCF): $74M (+13% YoY), quarterly record
  • Full-year 2025: constant-currency revenue growth 11%; non-GAAP operating margin 20.3% (+131 bps YoY); FCF nearly $216M (guidance >$150M)
  • 2026 guidance—EPS/tariff math: assumes ~12-month tariff impact of ~$15M (~$0.19/sh) vs ~$9M (~$0.12/sh) realized during last 8 months of 2025
  • 2026 guidance—margin: non-GAAP operating margin expected 20.6%–21% vs 20.3% in 2025 (implies +36 to +76 bps YoY)
  • 2026 guidance—revenue: GAAP net revenue growth 6%–8% (constant currency 5%–7%) including an expected 80 bps FX tailwind to GAAP; constant-currency organic revenue growth ~4.5%–6% excluding inorganic $13M–$15M BioLife + C2 contributions

AI IconCapital Funding

  • Balance sheet (Dec 31, 2025): cash & equivalents $446.4M; total debt obligations $747.5M; available borrowing capacity ~$697M; net leverage ratio 1.6x (adjusted)
  • 2026 FCF guide: at least $200M (inclusive of ~$90M capital expenditures)
  • Management reiterated minimum-FCF approach due to timing items that are hard to control

AI IconStrategy & Ops

  • Gross margin plan emphasized in Q&A: SKU rationalization, pricing, cost discipline, moving production to lower-cost areas while maintaining quality; manufacturing to lowest cost possible; R&D focused on launching the right products at the right price
  • R&D/launch focus and mix/geo optimization cited as ongoing drivers ('throw the kitchen sink' on gross margin)

AI IconMarket Outlook

  • 2026 guidance—Q1 2026 revenue: $375M–$380M (GAAP +6%–7% YoY; constant-currency +3%–5% YoY); organic growth +2%–3% excluding $6M–$7M inorganic contributions
  • 2026 guidance—Rhapsody CIE U.S. revenue: ~$7M vs $3M in FY2025

AI IconRisks & Headwinds

  • Tariffs: identified as a headwind to Q4 gross margin improvement with 112 bps incremental impact YoY; 2026 EPS explicitly includes tariff/trade policy impact of ~$0.07/sh
  • OEM demand softness: Q4 OEM sales decreased 15%, with softer-than-expected U.S. OEM performance attributed 'substantially' to customer inventory destocking; International OEM impacted by the macro environment
  • CPS product impact: CPS growth impacted by planned divestiture of DualCap line
  • Competitive pressure risk for Rhapsody: management noted the market 'supports a third player' but that competitors 'don’t stand still' after Rhapsody’s outpatient strategy launch

Sentiment: MIXED

Note: This summary was synthesized by AI from the MMSI Q4 2025 (reported Feb 25, 2026) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"MMSI reported revenues of $393.9M and a net income of $38.0M for the latest quarter. The operating cash flow stands at $98.5M with positive free cash flow of $76.9M, reflecting solid liquidity. However, the company has no dividends paid, indicating a focus on reinvestment rather than immediate shareholder returns. The total assets are $2.69B, with total liabilities of $1.10B, providing a strong equity cushion of $1.58B. Despite sound fundamentals, MMSI's shares have seen a significant decline, down 35.47% over the past year, indicating potential market concerns. Analysts have a consensus price target of $100.67, suggesting a possible upside from the current price of $67.55. The company's leverage ratio is reasonable, with a net debt of $449.7M against its equity, allowing for manageable risk if growth continues. In summary, while MMSI shows sound operational metrics, market performance has been negatively impacted, and careful monitoring is advised."

Revenue Growth

Neutral

The revenue is solid at $393.9M, though growth rates were not provided.

Profitability

Positive

Net income of $38.0M gives a respectable profit margin, but EPS indicates moderate profitability.

Cash Flow Quality

Good

Positive operating and free cash flow provides good liquidity and operational efficiency.

Leverage & Balance Sheet

Positive

Healthy balance sheet with total equity of $1.58B against liabilities suggest manageable risk.

Shareholder Returns

Neutral

No dividends paid and declining share price limit shareholder return potential.

Analyst Sentiment & Valuation

Neutral

Analyst price targets suggest some upside, but recent performance raises concerns.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
📁

SEC Filings (MMSI)

© 2026 Stock Market Info — Merit Medical Systems, Inc. (MMSI) Financial Profile